Tuberculosis Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Tuberculosis Treatment Market:By Class of Drugs (First Line Drugs, Second Line Drugs), By TB (TB, Multi Drug Resistance TB), by route of administration (Oral, Parental), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Tuberculosis Treatment Market size was valued at USD 1.7 billion in 2021 and is expected to grow at a CAGR of 6.1% during 2022 to 2028. Tuberculosis is the infectious disease usually caused by the bacteria Mycobacterium tuberculosis. TB usually affects lungs and transmits to the direct contact with the sputum of the infected person. Global Tuberculosis Treatment Market is projected to grow at significant rates owing to increase in prevalence of the immunosuppressant diseases such as HIV around the globe. HIV infected patients are very susceptible to be infected by TB. According to UNAIDS statistics, about 36.7 million people were living with the HIV in 2016. Companies operating in the global market focusing on new product developments and launches to maximize their share in the market. Furthermore, collaborations and acquisitions are also key strategies adopted by the companies to strengthen their position in the global market. For instance, in August 2017, Johnson & Johnson Servieces Inc. has entered into the partnership with Institute of Microbial Technology to accelerate the discovery of novel treatments for tuberculosis. The rising number of medicine recalls is a key stumbling block to the market’s expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis’ drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug. Another element limiting the market’s growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity. Although advanced technologies and the development of novel therapies are expected to reduce the time it takes to treat tuberculosis, most cases can take up to 6 months to treat with currently available drugs. Despite existing medicines and ongoing TB treatment drug advances, there is a constant need to increase patients’ access to appropriate TB medicines, particularly in the areas of MDR TB and paediatric TB.

Tuberculosis Treatment Market

MARKET SUMMARY
-
6.1%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 6.1%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Tuberculosis Treatment Market

  • The report on global tuberculosis treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of class of drugs, TB, route of administration, distribution channel and geography.
  • The tuberculosis treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Bayer AG (Germany)
  • AstraZeneca PLC (U.S.)
  • GlaxoSmithKline PLC (U.S.)
  • Eli Lilly And Company (U.S.)
  • Novartis AG (Switzerland )
Dynamics

Tuberculosis Treatment Market

Increase in the prevalence of the disease especially in developing countries is the major driving factor for the growth of tuberculosis treatment market globally. According to World health organization, there were 10.4 million tuberculosis cases were reported in 2016. In addition, growth in prevalence of multidrug-resistant tuberculosis and rise in awareness related to TB due to the initiatives by the various organization expected to boost the market growth over the forecast period. However, lack of reimbursement coverage in low and middle-income countries and high cost of development of drugs are expected to hamper the market growth over the forecast period.


North-America got significant share

Tuberculosis Treatment Market

Geographically, global tuberculosis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America tuberculosis treatment market is expected to grow at significant rates owing to the factors such as growing prevalence of the disease and presence of key market players in the region. Asia Pacific tuberculosis treatment market is expected to have lucrative growth opportunity owing to the low cost of drug development, high prevalence of the disease and comparatively low awareness related to disease especially in under developing countries. Furthermore, developing countries such as India and China expected to project notable growth over the forecast period owing to rising awareness and increase in R&D development.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market and forecast
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Tuberculosis Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Bayer AG (Germany)
  • AstraZeneca PLC (U.S.)
  • GlaxoSmithKline PLC (U.S.)
  • Eli Lilly And Company (U.S.)
  • Novartis AG (Switzerland )
  • Lupin Pharmaceuticals Inc. (India)
  • Sandoz International GmbH (Germany)
  • Pfizer Inc. (U.S.)
  • Johnson & Johnson Services Inc. (U.S.)
  • Sanofi S.A. (France)

Description

Tuberculosis Treatment Market size was valued at USD 1.7 billion in 2021 and is expected to grow at a CAGR of 6.1% during 2022 to 2028. Tuberculosis is the infectious disease usually caused by the bacteria Mycobacterium tuberculosis. TB usually affects lungs and transmits to the direct contact with the sputum of the infected person. Global Tuberculosis Treatment Market is projected to grow at significant rates owing to increase in prevalence of the immunosuppressant diseases such as HIV around the globe. HIV infected patients are very susceptible to be infected by TB. According to UNAIDS statistics, about 36.7 million people were living with the HIV in 2016. Companies operating in the global market focusing on new product developments and launches to maximize their share in the market. Furthermore, collaborations and acquisitions are also key strategies adopted by the companies to strengthen their position in the global market. For instance, in August 2017, Johnson & Johnson Servieces Inc. has entered into the partnership with Institute of Microbial Technology to accelerate the discovery of novel treatments for tuberculosis. The rising number of medicine recalls is a key stumbling block to the market’s expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis’ drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug. Another element limiting the market’s growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity. Although advanced technologies and the development of novel therapies are expected to reduce the time it takes to treat tuberculosis, most cases can take up to 6 months to treat with currently available drugs. Despite existing medicines and ongoing TB treatment drug advances, there is a constant need to increase patients’ access to appropriate TB medicines, particularly in the areas of MDR TB and paediatric TB.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX